Be The First To
Oxford BioMedica has no reservations about launching attacks on disease. The biotechnology company uses gene therapy and immunotherapy to develop treatments for cancer, as well as neurodegenerative and ocular diseases. Its four ocular gene therapies are partnered with Sanofi; the company works with Pfizer on another targeted antibody therapy. The company has three lead products: TroVax, ProSavin, and RetinoStat (being developed with Sanofi). TroVax is in late-stage clinical trials for the treatment of prostate cancer. ProSavin is being tested to treat Parkinson's disease...
This is the employer's chance to tell you why you should work for them. The information provided is from their perspective.
Working at Oxford BioMedica
Employees say it's “OK” 2 ratings
Not yet rated.
CEO and Director
Let us know if we're missing any workplace or industry recognition –